Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Part of Head and Neck Cancer

28 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Head and Neck Squamous Cell Carcinoma

77 trials tracked for Head and Neck Squamous Cell Carcinoma: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 812 citations.

77Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 8 Phase 2 60 Phase 1 6 Other / NA 2
  1. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 812 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) Completed · 81 cited
  3. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 61 cited
  4. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  5. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  6. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
Show 44 more trials
  1. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension Completed
  2. Phase 3 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed
  3. Phase 3 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed
  4. Phase 2 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Completed
  5. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  6. Phase 2 De-Escalation Therapy for Human Papillomavirus Negative Disease Completed
  7. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  8. Phase 2 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Completed
  9. Phase 2 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Completed
  10. Phase 2 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients Completed
  11. Phase 2 Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
  12. Phase 2 Expansion Trial for Axitinib In Head And Neck Cancer Completed
  13. Phase 2 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients Completed
  14. Phase 2 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Completed
  15. Phase 2 Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer Completed
  16. Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed
  17. Phase 2 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Completed
  18. Phase 2 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Completed
  19. Phase 2 ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
  20. Phase 2 Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Completed
  21. Phase 2 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Completed
  22. Phase 2 Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma Completed
  23. Phase 2 Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Completed
  24. Phase 2 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Completed
  25. Phase 2 Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  26. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  27. Phase 2 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Completed
  28. Phase 2 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Completed
  29. Phase 2 Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer Completed
  30. Phase 2 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Completed
  31. Phase 2 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Completed
  32. Phase 2 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Completed
  33. Phase 2 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Completed
  34. Phase 2 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Completed
  35. Phase 2 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Completed
  36. Phase 2 Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Completed
  37. Phase 2 IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Completed
  38. Phase 2 Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients Completed
  39. Phase 2 Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma Completed
  40. Phase 2 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Completed
  41. Phase 2 Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Completed
  42. Phase 2 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Completed
  43. Phase 2 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer Completed
  44. Phase 2 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck Completed

Showing the 50 most-cited and recently-updated of 77 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Head and Neck Squamous Cell Carcinoma: what the trials found

Several immunotherapies have been evaluated for Head and Neck Squamous Cell Carcinoma. Nivolumab demonstrated a statistically significant improvement in Overall Survival (OS) compared to the control group (p=0.0101) 11. Additionally, Pembrolizumab was evaluated across multiple trials; one study reported a 2-year Progression-free Survival (PFS) of 75.5% 3, and other studies confirmed its use in various cohorts [7, 20].

Lenvatinib showed significant improvements in Objective Response Rate (ORR) (p=0.0000019) 12 and Progression Free Survival (PFS) (p=0.0000037) 15 compared to standard treatments, although the difference in Overall Survival was not statistically significant in these trials [12, 15].

Cetuximab has been studied both as a monotherapy and in combination with radiotherapy; while it showed some efficacy, results for Progression-free Survival (p=0.8878) and Overall Survival (p=0.8175) did not reach statistical significance 13. A separate trial evaluating Cetuximab plus concomitant boost radiotherapy was also conducted [17, 18].

Alternative radiation modalities include stereotactic body radiotherapy 10, while the use of MEDI4736 in combination with Tremelimumab or as monotherapy did not show statistically significant differences in Overall Survival compared to standard of care in specific PD-L1 high subgroups 14.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a median Overall Survival of 14.9 months and a progression-free survival rate of 12% vs 7% in a small cohort 19.
  • Atezolizumab was associated with a 50.0% Pathologic Complete Response (pCR) rate compared to 16.7% in a small study, with no Grade 3 or higher immune-related adverse events reported 21.
  • Cisplatin treatment resulted in adverse event rates ranging from 21.9% to 38.5% across various categories 5.
  • Intensity modulated radiation therapy (IMRT) was associated with specific quality of life scores across several functional subscales 6.
  • Other recent investigations include paclitaxel/carboplatin 1, IO102-IO103 in combination with pembrolizumab 4, Nivolumab+Relatlimab 8, L-NMMA 9, and IPI-549 22.

For the clinician treating this condition

  • Nivolumab is associated with a statistically significant improvement in Overall Survival compared to standard treatments.
  • Lenvatinib provides significant improvements in Objective Response Rate (ORR) and Progression Free Survival (PFS), though it did not significantly impact Overall Survival in the studied cohorts.
  • Atezolizumab showed a high rate of Pathologic Complete Response (pCR) in a small cohort without reported high-grade immune-related adverse events.

AI synthesis of 16 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Plant extracts like curcumin and resveratrol may inhibit HNSCC growth via specific signaling pathways
Drug Pipeline Sys. Review
Plant extracts like curcumin and resveratrol may inhibit HNSCC growth via specific signaling pathways Plant extracts may slow growth of head and neck cancer
This systematic review examines the effects of plant extracts, including resveratrol, curcumin, quercetin, and anthocyanins, on head and nec…
Certain plant compounds like curcumin and resveratrol show promise in stopping cancer cell growth and resisting chemotherapy in lab studies.
Frontiers Sep 13, 2026
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure
ENT (Otolaryngology) Meta-analysis
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure Cetuximab shows activity for head and neck cancer patients
This meta-analysis evaluates cetuximab-based regimens for patients with recurrent or metastatic head and neck squamous cell carcinoma follow…
New data shows cetuximab-based treatments provide meaningful results for head and neck cancer patients after other treatments fail.
Sep 8, 2026
Immune cell-based therapy shows no significant benefits for tumor response or survival in HNSCC trials
ENT (Otolaryngology) Meta-analysis
Immune cell-based therapy shows no significant benefits for tumor response or survival in HNSCC trials Immune cell therapy shows limited promise for head and neck cancer
This meta-analysis of 30 trials involving 953 patients evaluated immune cell-based therapy (ICT) for head and neck squamous cell carcinoma. …
New data on immune cell-based therapies for head and neck cancer shows mixed results and a need for more rigorous testing.
Sep 8, 2026
Perioperative and postoperative immunotherapy timing determines clinical outcomes in locally advanced head and neck squamous cell carcinoma
Allergy & Immunology Sys. Review
Perioperative and postoperative immunotherapy timing determines clinical outcomes in locally advanced head and neck squamous cell carcinoma Timing of immunotherapy affects outcomes for head and neck cancer
This narrative review examines the impact of immunotherapy sequencing on patients with locally advanced head and neck squamous cell carcinom…
The timing of immunotherapy treatment significantly changes how well it controls local and distant spread in head and neck cancer.
Frontiers Sep 4, 2026
ALC decline greater than 0.74x10^9/L independently predicts poorer OS and PFS in LA-HNSCC
Allergy & Immunology RCT
ALC decline greater than 0.74x10^9/L independently predicts poorer OS and PFS in LA-HNSCC Lymphocyte Drop During Radiation Tied to Worse Head and Neck Cancer Outcomes
This post-hoc analysis of a phase III trial involved 222 patients with locally advanced head and neck squamous cell carcinoma. The study fou…
A large drop in lymphocytes during radiation for head and neck cancer is linked to poorer survival. This finding may help personalize treatm…
Frontiers Aug 31, 2026
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
Drug Pipeline Meta-analysis
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC Newer drugs show better survival for advanced head and neck cancer
This meta-analysis of 5 RCTs involving 1,700 patients found that PD-1/PD-L1 inhibitors resulted in superior overall survival (HR: 0.80) comp…
A review of clinical trials shows that certain immunotherapy drugs offer better survival rates and fewer severe side effects than traditiona…
Frontiers Aug 24, 2026
Pretreatment sarcopenia and low PNI are associated with worse survival in ICI-treated HNSCC
Geriatrics & Aging Meta-analysis
Pretreatment sarcopenia and low PNI are associated with worse survival in ICI-treated HNSCC Muscle Loss and Nutrition Linked to Survival in Head Cancer
This meta-analysis evaluates the prognostic impact of CT-based sarcopenia and nutritional indices on overall survival in patients with recur…
Low muscle mass and poor nutritional status are linked to worse survival outcomes for patients with advanced head and neck cancer.
Aug 4, 2026
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Oncology RCT
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
Jul 27, 2026
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
ENT (Otolaryngology) Meta-analysis
High tumor mutational burden correlates with improved objective response rate in HNSCC patients High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Jul 25, 2026
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ENT (Otolaryngology) Meta-analysis
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Combination therapies show promise for advanced head and neck cancer
This meta-analysis evaluated combination therapies involving targeted agents or immunotherapy with chemotherapy for patients with recurrent …
Combining immunotherapy or targeted drugs with chemotherapy may help patients with advanced head and neck cancer live longer without the dis…
Jul 25, 2026
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention
Oncology Meta-analysis
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention New data reveals management of head and neck cancer spread
This systematic review characterizes clinical features and management outcomes for patients with head and neck squamous cell carcinoma (HNSC…
Identifying how head and neck cancer spreads to the femur can help doctors provide better care and improve quality of life for patients.
Frontiers Jul 7, 2026
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC
Oncology Meta-analysis
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC Certain markers may predict how well immunotherapy treats head cancer
This meta-analysis of 26 studies involving 980 patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) found that hig…
New data suggests that specific biological markers can help doctors predict how well a patient's tumor will respond to immunotherapy.
NEJM Jun 29, 2026

Research across Head and Neck Cancer

Related studies from across the Head and Neck Cancer family.

Egg consumption associated with reduced glioma risk in Eastern populations and increased head and neck cancer risk
ENT (Otolaryngology) Meta-analysis
Egg consumption associated with reduced glioma risk in Eastern populations and increased head and neck cancer risk Egg consumption shows mixed links to glioma and head and neck cancer
This meta-analysis of observational studies involving 1,274,437 participants found that egg consumption was associated with a reduced risk o…
New data shows a link between egg consumption and lower glioma risk in some groups, but a potential link to higher head and neck cancer risk…
Sep 12, 2026
Radiation therapy and nasopharyngeal cancer significantly increase risk of chronic rhinosinusitis in head and neck cancer patients
ENT (Otolaryngology) Meta-analysis
Radiation therapy and nasopharyngeal cancer significantly increase risk of chronic rhinosinusitis in head and neck cancer patients Head and neck cancer treatments may increase risk of sinus issues
This meta-analysis of 3685 patients identifies a 0.37 pooled incidence of chronic rhinosinusitis in head and neck cancer patients. The analy…
Patients with head and neck cancers face a higher risk of developing chronic sinus inflammation, especially after radiation therapy.
Sep 12, 2026
IMRT plus cetuximab does not improve quality of life compared to IMRT plus cisplatin
ENT (Otolaryngology) RCT
IMRT plus cetuximab does not improve quality of life compared to IMRT plus cisplatin Trial compares cetuximab and cisplatin for oropharyngeal cancer quality of life
This Phase III randomized controlled trial of 375 patients with p16+ oropharyngeal cancer found no significant difference in quality of life…
A clinical trial found that replacing cisplatin with cetuximab did not improve quality of life or swallowing for patients with oropharyngeal…
Sep 12, 2026
Submental Artery Island Flap Shows 16% Pooled Locoregional Recurrence in Oral Cavity Reconstruction
ENT (Otolaryngology) Meta-analysis
Submental Artery Island Flap Shows 16% Pooled Locoregional Recurrence in Oral Cavity Reconstruction Submental artery island flap is a safe option for oral cancer
This meta-analysis pooled data on the submental artery island flap (SAIF) for oral cavity defects after oral squamous cell carcinoma resecti…
A specific surgical technique called the submental artery island flap shows a low recurrence rate for patients with oral cavity defects.
Sep 12, 2026
Empowered Survivor digital tool boosts self-efficacy in oral cancer survivors
Oncology RCT
Empowered Survivor digital tool boosts self-efficacy in oral cancer survivors Digital Intervention Improves Self-Care for Oral Cancer Survivors
In a randomized trial of 643 oral/oropharyngeal cancer survivors, the Empowered Survivor digital intervention improved self-efficacy at 2 an…
A new digital program helps oral cancer patients feel more confident and perform more self-care activities like swallowing and mobility exer…
Sep 10, 2026
Impact of Perineural Invasion on Survival Outcomes in Oral Squamous Cell Carcinoma
ENT (Otolaryngology) Meta-analysis
Impact of Perineural Invasion on Survival Outcomes in Oral Squamous Cell Carcinoma Perineural invasion linked to poorer outcomes in oral squamous cell carcinoma
A meta-analysis of 23,580 patients confirms that perineural invasion is a potent independent predictor of poor survival and high recurrence …
A large review of over 23,000 patients shows that cancer cells spreading along nerves are linked to higher recurrence and lower survival rat…
Sep 8, 2026
Higher pretreatment HALP score is associated with improved overall survival in head and neck cancer
ENT (Otolaryngology) Meta-analysis
Higher pretreatment HALP score is associated with improved overall survival in head and neck cancer Higher HALP scores linked to better survival in head cancer
This meta-analysis of 1759 patients found that a higher pretreatment HALP score is associated with improved overall survival (95% CI 0.41-0.…
A new analysis shows that a specific blood score can help doctors predict survival outcomes for patients with head and neck cancer.
Sep 8, 2026
AI-based MRI shows 0.82 AUC for detecting cervical lymph node metastases in oral squamous cell carcinoma
ENT (Otolaryngology) Meta-analysis
AI-based MRI shows 0.82 AUC for detecting cervical lymph node metastases in oral squamous cell carcinoma AI tools help detect lymph node spread in oral cancer
This meta-analysis of 548 patients evaluates AI-based MRI for detecting cervical lymph node metastases in oral squamous cell carcinoma. The …
Artificial intelligence may help doctors better identify if oral cancer has spread to lymph nodes before surgery.
Sep 8, 2026
C3-derived skeletal muscle index shows strong correlation with L3 index in head and neck cancer
Geriatrics & Aging Meta-analysis
C3-derived skeletal muscle index shows strong correlation with L3 index in head and neck cancer C3 Muscle Index Shows Strong Link to L3 Muscle Levels
This meta-analysis of 2017 patients evaluates the correlation between C3 and L3 skeletal muscle indices in head and neck cancer. The study f…
A new way to measure muscle mass in head and neck cancer patients may offer a simpler, radiation-sparing method for tracking muscle loss.
Sep 6, 2026
HPV16 constitutes 92.5% of single infections in oropharyngeal squamous cell carcinoma cases
Infectious Disease Meta-analysis
HPV16 constitutes 92.5% of single infections in oropharyngeal squamous cell carcinoma cases HPV16 Remains the Most Common Type in Throat Cancer
This meta-analysis of 183 studies involving 17,443 patients identifies HPV16 as the predominant genotype in oropharyngeal squamous cell carc…
A large global study of over 17,000 cases shows that HPV16 is the primary driver of most HPV-related throat cancers.
Sep 4, 2026
Higher preoperative neutrophil-to-lymphocyte ratio predicts poorer survival in oral squamous cell carcinoma patients
Oncology Meta-analysis
Higher preoperative neutrophil-to-lymphocyte ratio predicts poorer survival in oral squamous cell carcinoma patients High white blood cell ratios predict survival in oral cancer
This meta-analysis of 30 studies indicates that a higher preoperative neutrophil-to-lymphocyte ratio (NLR) is significantly associated with …
A high ratio of neutrophils to lymphocytes before surgery can help doctors predict survival outcomes for patients with oral squamous cell ca…
Sep 2, 2026
Small bowel metastasis from esophageal squamous cell carcinoma shows male predominance and 6-month median survival
Allergy & Immunology Meta-analysis
Small bowel metastasis from esophageal squamous cell carcinoma shows male predominance and 6-month median survival Small bowel spread from esophageal cancer has a short survival window
This systematic review of 23 patients with small bowel metastasis from esophageal squamous cell carcinoma found a strong male predominance (…
Patients with esophageal cancer that spreads to the small bowel often face a short survival window of about 6 months after diagnosis.
Frontiers Aug 31, 2026

Questions about Head and Neck Squamous Cell Carcinoma

What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?

Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.

Full answer →
Does reducing radiotherapy doses lower toxicity in head and neck squamous cell carcinoma?

Yes, reducing radiotherapy doses through margin reduction, adaptive planning, or proton therapy can lower acute and late toxicity in head and neck squamous cell carcinoma, though clinical benefits may be modest in unselected patients.

Full answer →
What are the risks of HPV-associated head and neck squamous cell carcinoma?

HPV-associated head and neck squamous cell carcinoma risks include persistent HPV infection (especially HPV16), distinct metabolic changes, and epigenetic dysregulation, but these tumors often have a better prognosis than HPV-negative cancers.

Full answer →
How do therapeutic cancer vaccines work for head and neck squamous cell carcinoma?

Therapeutic cancer vaccines train the immune system to recognize and attack HNSCC cells by targeting tumor-specific antigens, but achieving durable responses remains challenging.

Full answer →

All Head and Neck Squamous Cell Carcinoma Articles